1 – 10 of 118
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
- Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease
- Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma
- Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
- Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial
- Ability of an epigenetic assay to identify anterior prostate tumors based on a negative 12-core biopsy
- 2015
- Toxicities and doses of chemotherapy drugs in hyperthermic intraperitoneal chemotherapy (HIPEC)
- Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20⁺ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study
- Identification of a predictive signature based on immunohistochemical (IHC), RNA-seq and epigenetic profiling of melanoma metastases for response to ipilimumab-based immunotherapy
- Collaborative efforts driving progress in pediatric acute myeloid leukemia
- Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program